Volume 3.24 | Jun 25

Cancer Stem Cell News 3.24 June 25, 2014
Cancer Stem Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter
 
TOP STORY
The Colon Has a Safety Mechanism that Restricts Tumor Formation
Scientists have discovered that the colon has a safety mechanism to restrict the formation and growth of adenomas. They explain that bone morphogenetic protein limits the self-renewal capacity of adenoma stem cells, thus impeding the rapid development of the lesion. [Press release from the Institute for Research in Biomedicine Barcelona discussing online prepublication in Nature Cell Biology] Press Release | Abstract
Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
 
PUBLICATIONS (Ranked by impact factor of the journal)
Single-Cell RNA-Seq Highlights Intratumoral Heterogeneity in Primary Glioblastoma
Researchers used single-cell RNA sequencing (RNA-seq) to profile 430 cells from five primary glioblastomas, which they found to be inherently variable in their expression of diverse transcriptional programs related to oncogenic signaling, proliferation, complement/immune response, and hypoxia. [Science] Abstract

The Deubiquitinase USP28 Controls Intestinal Homeostasis and Promotes Colorectal Cancer
Using murine genetic models, scientists determined that USP28 antagonizes the ubiquitin-dependent degradation of c-MYC, a known USP28 substrate, as well as two additional oncogenic factors, c-JUN and NOTCH1, in the intestine. Mice lacking Usp28 had no apparent adverse phenotypes, but exhibited reduced intestinal proliferation and impaired differentiation of secretory lineage cells. [J Clin Invest] Full Article

CCK2R Identifies and Regulates Gastric Antral Stem Cell States and Carcinogenesis
Scientists generated CCK2 receptor (CCK2R)-CreERT mice and performed inducible lineage tracing experiments. CCK2R+ antral cells and Lgr5+ antral stem cells were cultured in a three-dimensional in vitro system. [Gut] Abstract

Oct4 Is a Critical Regulator of Stemness in Head and Neck Squamous Carcinoma Cells
Researchers investigated whether octamer-binding transcription factor 4 (Oct4) regulates stemness of head and neck squamous carcinoma cancer stem cells. They showed that ectopic expression of Oct4 promotes tumor growth through cyclin E activation, increases chemoresistance through ABCC6 expression and enhances tumor invasion through slug expression. [Oncogene] Abstract

IL-6 Enriched Lung Cancer Stem-Like Cell Population by Inhibition of Cell Cycle Regulators via DNMT1 Up-Regulation
Researchers demonstrate that IL-6 enriches the properties of lung cancer stem-like cells in A549 lung cancer cells cultured in spheroid medium. IL-6 also promotes sphere formation and stem-like properties of A549 cells by enhancing cell proliferation. [Int J Cancer] Abstract

iTEP Nanoparticle-Delivered Salinomycin Displays an Enhanced Toxicity to Cancer Stem Cells in Orthotopic Breast Tumors
Scientists sought to devise a nanoparticle carrier to deliver salinomycin to solid tumors through the enhanced permeability and retention effect and, hence, to increase its exposure to cancer stem cells. [Mol Pharm] Abstract

Light-Triggered, Efficient Cytosolic Release of IM7-Saporin Targeting the Putative Cancer Stem Cell Marker CD44 by Photochemical Internalization
Researchers used seven different human cancer cell lines of various origins to investigate the cytotoxic effect of photochemical internalization-based targeting of the cancer stem cell marker CD44. [Mol Pharm] Abstract

Decreased Camptothecin Sensitivity of the Stem-Cell-Like Fraction of Caco2 Cells Correlates with an Altered Phosphorylation Pattern of Topoisomerase I
The CD44+ and CD44 subpopulations of the colorectal cancer cell line Caco2 were analyzed separately for their sensitivities to the antitumor drug camptothecin. CD44+ cells were less sensitive to camptothecin than CD44 cells. [PLoS One] Full Article

Identification of CD24 as a Cancer Stem Cell Marker in Human Nasopharyngeal Carcinoma
Researchers showed that CD24+ cells isolated from human nasopharyngeal carcinoma cell lines express stem cell genes, and show activation of the Wnt/β-catenin signaling pathway. [PLoS One] Full Article

Side Population Cells of Pancreatic Cancer Show Characteristics of Cancer Stem Cells Responsible for Resistance and Metastasis
Researchers isolated side population cells from the highly aggressive and metastatic human pancreatic cancer cell line L3.6pl and evaluate their potential role as models for cancer stem cells. [Target Oncol] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
A Role for Cancer Stem Cells in Therapy Resistance: Cellular and Molecular Mechanisms
The authors describe the mechanisms of cancer stem cell-related therapy resistance including drug efflux by ABC transporters, activation of aldehyde dehydrogenase and developmental pathways, enhanced DNA damage response, autophagy and microenvironmental conditions, and discuss possible therapeutic strategies for improving cancer treatment. [Semin Cancer Biol] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
 
INDUSTRY NEWS
GlycoMimetics Initiates First Clinical Trial of GMI-1271 as Potential Treatment for Blood-Related Cancers
GlycoMimetics, Inc. announced that the first healthy volunteer has been dosed in a Phase I clinical study designed to evaluate the safety, tolerability and pharmacokinetics of GMI-1271. GlycoMimetics is initially exploring the clinical use of the drug candidate to treat acute myeloid leukemia following preclinical studies of GMI-1271 for blood cancers and other cancers that are associated with elevated risk of metastasis and thrombosis. [GlycoMimetics, Inc.] Press Release

Phase III First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase III study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma was stopped early because an analysis conducted by the independent data monitoring committee showed evidence of superior overall survival in patients receiving nivolumab compared to the control arm. [Bristol-Myers Squibb Company] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2014 Best of American Society of Clinical Oncology (ASCO) Seattle Meeting
August 22-23, 2014
Seattle, United States

Visit our events page to see a complete list of events in the cancer stem cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Assistant/Research Associate – Stem Cell and Cancer Biology (University of North Texas Health Science Center)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine in New York)

Postdoctoral Fellow – Cancer and Stem Cell Biology (University of Pennsylvania)

Research Officers – Cancer Stem Cell Biology (Genome Institute of Singapore)

PhD Scholarship – Inorganic Nanoparticles for Cancer Stem Cell Targeting and Detection (The Italian Institute of Technology)

Positions for Principal Investigators – Translational Medical Research of Cancer Biology (Shanghai Institute of Biochemistry and Cell Biology)

Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health and Science University)

Postdoctoral Researcher – Cancer Genomics (University of Chicago)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cancer Stem Cell News: Archives | Events | Contact Us